Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study
Even with liver-targeted therapies, uveal melanoma with hepatic metastasis remains a challenge. The aim of this study was to compare the outcome of patients treated with either SIRT or CS-PHP. We included 62 patients with hepatic metastasized uveal melanoma (n = 34 with SIRT, receiving 41 cycles; n...
Gespeichert in:
| Veröffentlicht in: | Cancers 2023-10, Vol.15 (20), p.4942 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 20 |
| container_start_page | 4942 |
| container_title | Cancers |
| container_volume | 15 |
| creator | Kolb, Manuel Forschner, Andrea Artzner, Christoph Grözinger, Gerd Said, Ines Dittmann, Helmut Seith, Ferdinand |
| description | Even with liver-targeted therapies, uveal melanoma with hepatic metastasis remains a challenge. The aim of this study was to compare the outcome of patients treated with either SIRT or CS-PHP. We included 62 patients with hepatic metastasized uveal melanoma (n = 34 with SIRT, receiving 41 cycles; n = 28 with CS-PHP, receiving 56 cycles) that received their treatments between 12/2013 and 02/2020 at a single center. We evaluated their response according to the RECIST 1.1, as well as progression-free survival (PFS) and overall survival (OS), after the initiation of the first cycle of the liver-directed treatment using Cox regression, adjusted via propensity score analysis for confounders, including the amount of hepatic involvement. The disease control rate was 18% for SIRT and 30% for CS-PHP. The median (range) of PFS was 127.5 (19–1912) days for SIRT and 408.5 (3–1809) days for CS-PHP; adjusted Cox regression showed no significant difference (p = 0.090). The median (range) of OS was 300.5 (19–1912) days for SIRT and 516 (5–1836) days for CS-PHP; adjusted Cox regression showed a significant difference (p = 0.006). In our patient cohort, patients treated with CS-PHP showed a significantly longer OS than patients treated with SIRT. CS-PHP might therefore be preferable for patients with liver-dominant metastatic uveal melanoma. |
| doi_str_mv | 10.3390/cancers15204942 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10605323</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2883585058</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-612a7f4bb124b4db60ad1d38522afb35d5a83cdec52f2ef53afe1e1f15619b9d3</originalsourceid><addsrcrecordid>eNpdkk1r3DAQhk1paUKac6-CXjYHN_qw_NFLCSbtLiR02U3OZiyNuw625Urywvb_9H9Wzi6hjRjQMPPwzjAzUfSR0c9CFPRawaDQOiY5TYqEv4nOOc14nKZF8vYf_yy6dO6JhicEy9LsfXQmsrxIBC3Ooz9b7FD5do9kNXi0A3RkA7o1focWxgNZbFebhysCgyblDnvjwE8WfGsGskarJg8DmsmRJY4hquZgM7k5vSi38Xq5viKNseQePbhg7W_U5HGPocw9djCYHr6QG7JBb40bT52Uph9hLhL8rZ_04UP0roHO4eXpv4gev90-lMv47sf3VXlzFytRFD5OGYesSeqa8aROdJ1S0EyLXHIOTS2klpALpVFJ3nBspIAGGbKGyZQVdaHFRfT1qDtOdY9a4eAtdNVo2x7soTLQVv9nhnZX_TT7itGUSsFFUFicFKz5NaHzVd86hV13HFPF81zIXFKZB_TTK_TJTPMCnqmgJXjGAnV9pFQYkLPYvHTDaDWfQfXqDMRfsw-o5Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2882333271</pqid></control><display><type>article</type><title>Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kolb, Manuel ; Forschner, Andrea ; Artzner, Christoph ; Grözinger, Gerd ; Said, Ines ; Dittmann, Helmut ; Seith, Ferdinand</creator><creatorcontrib>Kolb, Manuel ; Forschner, Andrea ; Artzner, Christoph ; Grözinger, Gerd ; Said, Ines ; Dittmann, Helmut ; Seith, Ferdinand</creatorcontrib><description>Even with liver-targeted therapies, uveal melanoma with hepatic metastasis remains a challenge. The aim of this study was to compare the outcome of patients treated with either SIRT or CS-PHP. We included 62 patients with hepatic metastasized uveal melanoma (n = 34 with SIRT, receiving 41 cycles; n = 28 with CS-PHP, receiving 56 cycles) that received their treatments between 12/2013 and 02/2020 at a single center. We evaluated their response according to the RECIST 1.1, as well as progression-free survival (PFS) and overall survival (OS), after the initiation of the first cycle of the liver-directed treatment using Cox regression, adjusted via propensity score analysis for confounders, including the amount of hepatic involvement. The disease control rate was 18% for SIRT and 30% for CS-PHP. The median (range) of PFS was 127.5 (19–1912) days for SIRT and 408.5 (3–1809) days for CS-PHP; adjusted Cox regression showed no significant difference (p = 0.090). The median (range) of OS was 300.5 (19–1912) days for SIRT and 516 (5–1836) days for CS-PHP; adjusted Cox regression showed a significant difference (p = 0.006). In our patient cohort, patients treated with CS-PHP showed a significantly longer OS than patients treated with SIRT. CS-PHP might therefore be preferable for patients with liver-dominant metastatic uveal melanoma.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15204942</identifier><identifier>PMID: 37894309</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Disease ; Disease control ; Interdisciplinary aspects ; Liver ; Liver diseases ; Melanoma ; Metastases ; Metastasis ; Nuclear medicine ; Patients ; Perfusion ; Radiation therapy ; Scanners ; Survival ; Variables</subject><ispartof>Cancers, 2023-10, Vol.15 (20), p.4942</ispartof><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-612a7f4bb124b4db60ad1d38522afb35d5a83cdec52f2ef53afe1e1f15619b9d3</citedby><cites>FETCH-LOGICAL-c399t-612a7f4bb124b4db60ad1d38522afb35d5a83cdec52f2ef53afe1e1f15619b9d3</cites><orcidid>0000-0001-6840-5571 ; 0000-0002-6185-4945 ; 0000-0002-9696-2954</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605323/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605323/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids></links><search><creatorcontrib>Kolb, Manuel</creatorcontrib><creatorcontrib>Forschner, Andrea</creatorcontrib><creatorcontrib>Artzner, Christoph</creatorcontrib><creatorcontrib>Grözinger, Gerd</creatorcontrib><creatorcontrib>Said, Ines</creatorcontrib><creatorcontrib>Dittmann, Helmut</creatorcontrib><creatorcontrib>Seith, Ferdinand</creatorcontrib><title>Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study</title><title>Cancers</title><description>Even with liver-targeted therapies, uveal melanoma with hepatic metastasis remains a challenge. The aim of this study was to compare the outcome of patients treated with either SIRT or CS-PHP. We included 62 patients with hepatic metastasized uveal melanoma (n = 34 with SIRT, receiving 41 cycles; n = 28 with CS-PHP, receiving 56 cycles) that received their treatments between 12/2013 and 02/2020 at a single center. We evaluated their response according to the RECIST 1.1, as well as progression-free survival (PFS) and overall survival (OS), after the initiation of the first cycle of the liver-directed treatment using Cox regression, adjusted via propensity score analysis for confounders, including the amount of hepatic involvement. The disease control rate was 18% for SIRT and 30% for CS-PHP. The median (range) of PFS was 127.5 (19–1912) days for SIRT and 408.5 (3–1809) days for CS-PHP; adjusted Cox regression showed no significant difference (p = 0.090). The median (range) of OS was 300.5 (19–1912) days for SIRT and 516 (5–1836) days for CS-PHP; adjusted Cox regression showed a significant difference (p = 0.006). In our patient cohort, patients treated with CS-PHP showed a significantly longer OS than patients treated with SIRT. CS-PHP might therefore be preferable for patients with liver-dominant metastatic uveal melanoma.</description><subject>Disease</subject><subject>Disease control</subject><subject>Interdisciplinary aspects</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Melanoma</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Nuclear medicine</subject><subject>Patients</subject><subject>Perfusion</subject><subject>Radiation therapy</subject><subject>Scanners</subject><subject>Survival</subject><subject>Variables</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkk1r3DAQhk1paUKac6-CXjYHN_qw_NFLCSbtLiR02U3OZiyNuw625Urywvb_9H9Wzi6hjRjQMPPwzjAzUfSR0c9CFPRawaDQOiY5TYqEv4nOOc14nKZF8vYf_yy6dO6JhicEy9LsfXQmsrxIBC3Ooz9b7FD5do9kNXi0A3RkA7o1focWxgNZbFebhysCgyblDnvjwE8WfGsGskarJg8DmsmRJY4hquZgM7k5vSi38Xq5viKNseQePbhg7W_U5HGPocw9djCYHr6QG7JBb40bT52Uph9hLhL8rZ_04UP0roHO4eXpv4gev90-lMv47sf3VXlzFytRFD5OGYesSeqa8aROdJ1S0EyLXHIOTS2klpALpVFJ3nBspIAGGbKGyZQVdaHFRfT1qDtOdY9a4eAtdNVo2x7soTLQVv9nhnZX_TT7itGUSsFFUFicFKz5NaHzVd86hV13HFPF81zIXFKZB_TTK_TJTPMCnqmgJXjGAnV9pFQYkLPYvHTDaDWfQfXqDMRfsw-o5Q</recordid><startdate>20231011</startdate><enddate>20231011</enddate><creator>Kolb, Manuel</creator><creator>Forschner, Andrea</creator><creator>Artzner, Christoph</creator><creator>Grözinger, Gerd</creator><creator>Said, Ines</creator><creator>Dittmann, Helmut</creator><creator>Seith, Ferdinand</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6840-5571</orcidid><orcidid>https://orcid.org/0000-0002-6185-4945</orcidid><orcidid>https://orcid.org/0000-0002-9696-2954</orcidid></search><sort><creationdate>20231011</creationdate><title>Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study</title><author>Kolb, Manuel ; Forschner, Andrea ; Artzner, Christoph ; Grözinger, Gerd ; Said, Ines ; Dittmann, Helmut ; Seith, Ferdinand</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-612a7f4bb124b4db60ad1d38522afb35d5a83cdec52f2ef53afe1e1f15619b9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Disease</topic><topic>Disease control</topic><topic>Interdisciplinary aspects</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Melanoma</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Nuclear medicine</topic><topic>Patients</topic><topic>Perfusion</topic><topic>Radiation therapy</topic><topic>Scanners</topic><topic>Survival</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kolb, Manuel</creatorcontrib><creatorcontrib>Forschner, Andrea</creatorcontrib><creatorcontrib>Artzner, Christoph</creatorcontrib><creatorcontrib>Grözinger, Gerd</creatorcontrib><creatorcontrib>Said, Ines</creatorcontrib><creatorcontrib>Dittmann, Helmut</creatorcontrib><creatorcontrib>Seith, Ferdinand</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kolb, Manuel</au><au>Forschner, Andrea</au><au>Artzner, Christoph</au><au>Grözinger, Gerd</au><au>Said, Ines</au><au>Dittmann, Helmut</au><au>Seith, Ferdinand</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study</atitle><jtitle>Cancers</jtitle><date>2023-10-11</date><risdate>2023</risdate><volume>15</volume><issue>20</issue><spage>4942</spage><pages>4942-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Even with liver-targeted therapies, uveal melanoma with hepatic metastasis remains a challenge. The aim of this study was to compare the outcome of patients treated with either SIRT or CS-PHP. We included 62 patients with hepatic metastasized uveal melanoma (n = 34 with SIRT, receiving 41 cycles; n = 28 with CS-PHP, receiving 56 cycles) that received their treatments between 12/2013 and 02/2020 at a single center. We evaluated their response according to the RECIST 1.1, as well as progression-free survival (PFS) and overall survival (OS), after the initiation of the first cycle of the liver-directed treatment using Cox regression, adjusted via propensity score analysis for confounders, including the amount of hepatic involvement. The disease control rate was 18% for SIRT and 30% for CS-PHP. The median (range) of PFS was 127.5 (19–1912) days for SIRT and 408.5 (3–1809) days for CS-PHP; adjusted Cox regression showed no significant difference (p = 0.090). The median (range) of OS was 300.5 (19–1912) days for SIRT and 516 (5–1836) days for CS-PHP; adjusted Cox regression showed a significant difference (p = 0.006). In our patient cohort, patients treated with CS-PHP showed a significantly longer OS than patients treated with SIRT. CS-PHP might therefore be preferable for patients with liver-dominant metastatic uveal melanoma.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>37894309</pmid><doi>10.3390/cancers15204942</doi><orcidid>https://orcid.org/0000-0001-6840-5571</orcidid><orcidid>https://orcid.org/0000-0002-6185-4945</orcidid><orcidid>https://orcid.org/0000-0002-9696-2954</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2023-10, Vol.15 (20), p.4942 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10605323 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Disease Disease control Interdisciplinary aspects Liver Liver diseases Melanoma Metastases Metastasis Nuclear medicine Patients Perfusion Radiation therapy Scanners Survival Variables |
| title | Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T09%3A03%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selective%20Internal%20Radiotherapy%20(SIRT)%20and%20Chemosaturation%20Percutaneous%20Hepatic%20Perfusion%20(CS-PHP)%20for%20Metastasized%20Uveal%20Melanoma:%20A%20Retrospective%20Comparative%20Study&rft.jtitle=Cancers&rft.au=Kolb,%20Manuel&rft.date=2023-10-11&rft.volume=15&rft.issue=20&rft.spage=4942&rft.pages=4942-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15204942&rft_dat=%3Cproquest_pubme%3E2883585058%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2882333271&rft_id=info:pmid/37894309&rfr_iscdi=true |